Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Clinical Trials in Rochester, Minnesota

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy